Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"